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Abstract Carbamylation refers to chemical modi¢cation of
protein side chains by cyanate derived e.g. from urea. It alters
their structural and functional properties. We have studied the
in£uence of the carbamylation of type I collagen in vitro on its
interactions with elutriated human monocytes, and its potential
role in atherosclerosis. Adhesion of monocytes onto carbamy-
lated collagen was signi¢cantly enhanced compared to native
collagen. There was no change in superoxide anion production.
On the other hand, there was an increase in the production and
the activation of matrix metalloproteinase-9. No e¡ect was
found on tissue inhibitor of metalloproteinase-1 production.
Thus, the presence of carbamylated collagen may stimulate
the remodelling of extracellular matrix mediated by activated
monocytes. Such alterations may contribute to enhanced athero-
sclerosis in renal insu⁄ciency, a pathological condition associ-
ated with elevated levels of carbamylation.
( 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Many cell functions such as protein synthesis are controlled
by direct interactions with extracellular matrix (ECM) com-
ponents, which trigger various transduction pathways [1].
However, such interactions cannot be considered without
reference to the post-translational modi¢cations of proteins,
which occur throughout their lifespan in vivo and are charac-
terized by non-enzymatic binding of various low molecular
weight molecules to amino groups of proteins. These cumu-
lative modi¢cations not only alter protein structure, but also
impair protein interactions with surrounding cells and trigger
deleterious reactions. Because of their long biological half-life,
ECM proteins, among them type I collagen, represent prefer-
ential targets for post-translational reactions. For instance,
collagen glycoxidation, due mainly to the binding of glucose,
is involved in pathophysiology of ageing, diabetes mellitus,
and other pathologies including atherosclerosis [2]. Athero-
sclerosis is a complex process involving a variety of events
which have still been only partially elucidated [3]. A critical
factor in its progression is vessel wall remodelling, conditioned
by the local in£ammatory status and the balance between
degradative and reparative reactions. ECM proteins play a
pivotal role in this process, mainly through their interactions
with in£ammatory cells such as monocytes, which are known
to be actively involved in the development of atherosclerosis
[4^6].
One recently revealed post-translational modi¢cation of
proteins is carbamylation [7]. The process occurs physiologi-
cally in humans and is based on covalent binding of isocyanic
acid, a decomposition product of urea, to proteins. Elevated
levels of carbamylated proteins are seen in renal insu⁄ciency,
especially in uremic patients [8]. However, the consequences
of carbamylation on cell^matrix interactions are still poorly
understood.
We have previously shown that type I collagen elicits adhe-
sion and activation of human blood monocytes via interaction
with KxL2 integrin [9]. Protein carbamylation has been pro-
posed as a causal factor of atherosclerosis, particularly in
renal insu⁄ciency [10]. Therefore, it was of interest to study
the in£uence of collagen carbamylation on its interactions
with monocytes. We have found in this study that carbamy-
lated collagen selectively regulates metabolic functions of
monocytes, favoring their adhesion and matrix metalloprotei-
nase-9 (MMP-9) release, thus increasing the in£ammatory po-
tential of monocytes and their ability to remodel ECM.
2. Materials and methods
2.1. Reagents
Chemicals were purchased from Sigma (St. Louis, MO, USA), un-
less otherwise mentioned. Reagents for cell cultures were from Life
Technologies (Cergy-Pontoise, France).
2.2. Preparation of carbamylated collagen
Acid-soluble type I collagen was prepared from Sprague^Dawley
rat tail tendons by 0.5 M acetic acid extraction [9], and carbamylated
by incubation with 0.1 M KCNO in 0.15 M phosphate bu¡er, pH 7.4,
for 6 h at 37‡C [11]. Control series were prepared in the presence of
0.1 M KCl. After incubation, collagen was extensively dialyzed
against water, until no potassium could be detected by £ame photo-
metry (Chiron Diagnostics, model 480). Subsequently, collagen was
lyophilized and solubilized in 18 mM acetic acid (2 mg/ml). In vitro
carbamylation generated four residues of homocitrulline from lysine
residues per 1000 amino acid residues (one K1 chain of type I collagen
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contains 1056 residues), as evaluated by anion exchange chromatog-
raphy (Hitachi 880 analyzer, Roche Diagnostics).
2.3. Cell incubations
Monocytes were prepared by elutriation from whole blood obtained
with informed consent from healthy volunteers [9]. The purity of the
preparations (percentage of CD14-positive cells) and cell viability (try-
pan blue exclusion test) were respectively higher than 95% and 98%.
Ninety-six-well plates were coated with either untreated or carba-
mylated collagen, 25 Wg per well, washed three times with Dulbecco’s
solution and saturated for 2 h at 37‡C with 100 Wl of 2% (w/v) bovine
serum albumin, then washed three more times before cell addition.
The amount of control or carbamylated collagen bound to plastic
wells was veri¢ed by 4-hydroxyproline assay [12]: 2.25Q 0.22 Wg of
4-hydroxyproline in control collagen-coated wells vs. 2.18Q 0.25 Wg in
carbamylated collagen-coated wells.
2.4. Measurement of cell adhesion and superoxide anion (O32 )
production
Cell adhesion was measured at 37‡C by staining cell nuclei with
crystal violet. 1.5U105 cells were incubated from 0 to 6 h, and the
number of adherent cells was calculated from a standard calibration
curve [9].
O32 production was measured by the superoxide dismutase-inhibit-
able reduction of ferricytochrome c, using monocytes in suspension,
as previously described [13]. Brie£y, 1.5U106 monocytes were sus-
pended in 850 Wl of Dulbecco’s solution supplemented with 100 Wl
of 1 mM ferricytochrome c solution. O32 production was evaluated
after addition of 100 Wl of a 2 mg/ml solution of collagen I in 18 mM
acetic acid. The increase in absorbance at 550 nm was evaluated
spectrophotometrically, test tubes supplemented with 50 Wl of a
1000 U/ml superoxide dismutase solution being used as blanks to
assess the speci¢city of the reaction.
2.5. Evaluation of MMP-9 and TIMP-1 production
MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1)
amounts were quantitatively assayed in 100 Wl culture medium by
two-site enzyme-linked immunosorbent assay (ELISA) sandwich kits
(Biotrak RPN2614 and Biotrak RPN2611 respectively, Amersham
Pharmacia Biotech, Buckinghamshire, UK). These methods evaluated
total MMP-9 (pro-MMP-9 and pro-MMP-9^TIMP-1 complexes) and
total TIMP-1 (free and MMP-complexed TIMP-1).
MMP-9 activity was evaluated by sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis (SDS^PAGE) zymography, which al-
lowed the determination of latent and activated forms, as previously
described [14]. Culture medium (20 Wg proteins) was subjected to elec-
trophoresis under non-reducing conditions in a SDS^9% polyacryl-
amide gel containing 1 mg/ml gelatin. Gels were incubated overnight
at 37‡C in 50 mM Tris^HCl, 150 mM NaCl, 10 mM CaCl2 bu¡er, pH
7.4, then stained with Coomassie brilliant blue. Unstained areas cor-
responding to gelatinolytic activities were quanti¢ed by image analysis
(Vilbert-Lourmat, Marne La Valle¤e, France).
TIMP identi¢cation was assessed by gelatin reverse zymography.
Culture medium (1 Wg proteins) was subjected to electrophoresis in
SDS^15% polyacrylamide gels containing 1 mg/ml gelatin and 20 ng/
ml pro-MMP-2. Reverse zymography revealed inhibitory activity,
which appeared as blue zones against a clear background, demon-
strating inhibition of gelatin lysis in the gels.
3. Results
3.1. E¡ect of collagen carbamylation on monocyte adhesion
and O32 production
Monocytes seeded on untreated acid-soluble collagen-
coated plates gradually adhered to the substratum, reaching
a plateau after 2 h incubation. A signi¢cantly higher number
of monocytes adhered to carbamylated collagen. Kinetic anal-
yses also showed that adhesion occurred faster (+44% at
30 min, P6 0.001) and reached a higher plateau level (+52%
after 3 h, P6 0.001) (Fig. 1A).
By contrast, no change was seen in O32 amount produced
when the cells adhered to carbamylated collagen as compared
to untreated collagen (Fig. 1B).
3.2. E¡ect of collagen carbamylation on MMP-9 production
and activation by monocytes
The contact of monocytes with carbamylated collagen
strongly enhanced both production and activation of MMP-
9 when compared to untreated collagen (Fig. 2A). This e¡ect
occurred in a time-dependent manner. In the presence of un-
treated collagen, total MMP-9 gradually increased in the cul-
ture medium, reaching about three times the 6-h level after
24 h incubation. A highly accelerated MMP-9 production was
seen on carbamylated collagen: increases of 46% vs. control
after 6 h (P6 0.001), and 70% (P6 0.001) after 24 h (Fig. 2B).
After 24 h, MMP-9 concentrations, as measured by ELISA in
culture medium, were 10.8Q 3.7 ng/ml in control series (KCl-
Fig. 1. E¡ect of collagen carbamylation on monocyte adhesion (A)
and O32 production (B). A: Monocytes were seeded in wells coated
with untreated (8) or carbamylated (F) type I collagen. The num-
ber of adherent cells was determined by measurement of absorbance
at 560 nm using the crystal violet method and a standard cali-
bration curve. Results are the means of four experimentsQ S.E.M.
Signi¢cant di¡erence (Student’s t-test) between the two series:
*P6 0.001. B: Monocytes were incubated in suspension with un-
treated (8) or carbamylated (F) type I collagen, and O32 production
measured by the superoxide dismutase-inhibitable reduction of ferri-
cytochrome c. Results are the means of four experimentsQ S.E.M.
No signi¢cant di¡erence was found between the two series.
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incubated collagen) vs. 18.8 Q 4.1 ng/ml in monocytes culti-
vated on carbamylated collagen (P6 0.001).
The activation of pro-MMP-9 to active MMP-9 was also
increased upon carbamylated collagen. After 6 h, only the
84-kDa active form could be found in culture medium of
monocytes adhering to untreated collagen, at very low levels
(6 1.5% of total MMP-9), whereas the two activated forms
(84 and 78 kDa) were present in the culture medium of mono-
cytes incubated with carbamylated collagen. The activation of
MMP-9 induced by carbamylated collagen increased progres-
sively with time, the percentage of active forms being 4.1%,
8.0%, 12.2% at 6 h, 12 h and 24 h respectively, vs. 1.4%, 2.5%, 3.8% in control conditions. The di¡erence was highly signi¢-
cant (P6 0.001) at all times (Fig. 2C).
3.3. E¡ect of collagen carbamylation on TIMP-1 production by
monocytes
Contact of monocytes with carbamylated collagen was not
associated with the production of the major physiological in-
hibitor of MMP-9, TIMP-1, when compared to untreated
collagen (Fig. 3). After 24 h incubation, TIMP-1 concentra-
tions, as measured by ELISA in culture medium, were
820Q 83 ng/ml in control series vs. 851Q 78 ng/ml in mono-
cytes cultivated on carbamylated collagen (+3.8%, NS). No
signi¢cant change of TIMP-2 production was noticed by re-
verse zymography.
4. Discussion
Carbamylation results from the non-enzymatic binding of
urea-derived cyanate to amino groups of proteins, especially
to lysine residues, generating homocitrulline [7,15]. This reac-
tion is increased in vivo by renal insu⁄ciency [8,15]. Studies
have shown that carbamylation of plasma proteins and hemo-
globin was increased in patients with renal insu⁄ciency. How-
ever, there is very little literature on the carbamylation of
tissue proteins. The presence of homocitrulline in kidneys of
patients with renal insu⁄ciency has been shown in one study
[16], but no quantitative results have been reported. Consid-
ering the long lifespan of ECM proteins and with reference to
the accumulation of glycoxidation end-products in various
diseases [2], we may expect a much higher rate of carbamyla-
tion in tissue proteins than in circulating proteins. The con-
centration of potassium cyanate used in our study to carba-
mylate collagen is compatible with the ones used by others in
in vitro studies on the e¡ects of serum carbamylated proteins
on cultured mesangial cells [17], or on the e¡ects of cyanate
on isolated polymorphonuclear neutrophils [15]. In our exper-
imental procedures, four homocitrulline residues were formed
per 1000 amino acid residues, which is a lower rate than that
obtained by Shaykh et al. (10 per 1000) for carbamylated
serum proteins [17].
Atherosclerosis, a major complication of renal insu⁄ciency,
is not fully explained by conventional risk factors. Previous
studies have suggested that the carbamylation of low density
lipoproteins could enhance their oxidation, and thus promote
atherogenesis [10]. More recently, carbamylation has been
shown to alter structural and/or functional properties of
ECM proteins: in glomerular mesangial cells for instance,
carbamylated proteins stimulate collagen deposition [17].
Such ¢ndings point out the potential role of protein carbamy-
lation in atherosclerosis related to renal insu⁄ciency.
We have therefore studied how the carbamylation of colla-
Fig. 2. E¡ect of collagen carbamylation on MMP-9 production and
activation by monocytes. Monocytes were incubated with untreated
(1, 8), carbamylated (2, F) or KCl-incubated (3, b) collagen for up
to 24 h. Conditioned media were analyzed by gelatin zymography
(20 Wg protein per well). MMP-9 bands were evaluated by densito-
metric evaluation. Results are the means of four determinations Q
S.E.M. Signi¢cant di¡erence (Student’s t-test) between control and
KCl-incubated collagens vs. carbamylated collagen: *P6 0.001. A:
Gelatin zymography of conditioned media after 24 h incubation.
Latent MMP-9 (MW=92 kDa) and active forms of MMP-9
(MW=84 kDa and 78 kDa) are indicated by arrows. B: Kinetics of
MMP-9 production. Every point indicates the production of total
MMP-9 (latent+active forms). C: Kinetics of MMP-9 activation.
Every point represents the ratio activated MMP-9U100/total MMP-
9.
Fig. 3. E¡ect of collagen carbamylation on TIMP-1 and TIMP-2
production by monocytes. Monocytes were incubated with untreated
(1), KCl-incubated (2) or carbamylated (3) collagen for up to 24 h.
Conditioned media were analyzed by gelatin reverse zymography
(1 Wg protein per lane).
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gen, a long-lived tissue protein, altered its interactions with
monocytes. Monocytes play an essential role in the initiation
and progression of atherosclerosis through their pro-in£am-
matory properties that contribute to the destabilization of
atheroma plaque, leading to super¢cial erosions or rupture
of the plaque [18]. As a matter of fact, monocytes synthesize
various components that in£uence ECM plaque remodelling,
including reactive oxygen species and MMPs [6,19]. Circulat-
ing monocytes are attracted by numerous cytokines or chemo-
kines to the atherogenic sites of vessel walls, undergo trans-
endothelial migration, interact with type I collagen through
CD11c/CD18 integrin [9], and di¡erentiate to macrophages
that contribute to the constitution of the plaque.
We have shown here that carbamylation altered the ability
of type I collagen to modulate monocyte functions. Firstly,
the number of monocytes adherent to carbamylated collagen
was much higher than the number of monocytes adherent to
untreated collagen, which suggests that monocytes interact
more closely with the ECM, for example in blood vessels,
when carbamylation is increased. Secondly, we found that
the increased binding of monocytes was accompanied by a
strong stimulation of active MMP-9 production, correspond-
ing to an increased ability of monocytes to degrade surround-
ing ECM. Overexpression of MMP-9 increases the risk of
rupture of the ¢brous cap of the atherosclerotic plaque, and
represents a key event in triggering thrombotic events like
vascular cerebral accidents or acute coronary syndromes. In
addition, MMPs signi¢cantly modulate cellular functions, and
knockout of various MMP genes in mice has clearly demon-
strated their link with the atherosclerosis process, as reviewed
elsewhere [20]. In our experiments, the increased MMP-9 se-
cretion and activation were not correlated with an altered
production of its major inhibitor, TIMP-1, whereas no e¡ect
on oxygen free radical production was noticed, suggesting
that other in£ammatory properties of monocytes were not
stimulated. The mechanism of this interaction is currently
under investigation. Other studies have reported that various
ECM components (e.g. laminin peptides) could modulate
monocyte functions [21], thus explaining some of their roles
in atherogenesis [18]. Our ¢ndings suggest an increased adhe-
sion and a sustained activity of monocytes in carbamylated
tissues, and provide novel insights into the pathophysiology of
atherosclerosis, particularly in renal insu⁄ciency.
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